Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144879 | 0.92 | CYP2C19 (0.38) | CYP2C19YTHDC1HSD17B10GAAALDH1A1 | |
| SCHEMBL17048216 | 0.84 | GAA (0.48) | HSD17B10GAAALDH1A1HPGDNPC1 | |
| SCHEMBL14251130 | 0.83 | GAA (0.50) | HSD17B10GAAALDH1A1HPGDNPC1 | |
| SCHEMBL17678210 | 0.82 | GAA (0.45) | HSD17B10GAAALDH1A1HPGDNPC1 | |
| SCHEMBL17678207 | 0.82 | GAA (0.41) | HSD17B10GAAALDH1A1HPGDNPC1 | |
| SCHEMBL17042063 | 0.81 | IRAK4 (0.35) | HSD17B10GAAALDH1A1HPGDNPC1 | |
| SCHEMBL30854893 | 0.81 | HCAR3 (0.40) | ALDH1A1TP53SMN1; SMN2TSHRHIF1A | |
| SCHEMBL21929417 | 0.81 | HCAR3 (0.40) | ALDH1A1TP53SMN1; SMN2TSHRHIF1A | |
| SCHEMBL29521835 | 0.80 | CYP2C19 (0.42) | CYP2C19YTHDC1HSD17B10ALDH1A1HPGD | |
| SCHEMBL138573 | 0.80 | CYP2C19 (0.42) | CYP2C19YTHDC1HSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452216-B | Anti-fibrotic pyridinones | 英特穆恩公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | CYP2C19 4508/4885YTHDC1 4135/4885HSD17B10 2171/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | CYP2C19 4508/4885YTHDC1 4135/4885HSD17B10 2171/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CYP2C19 2192/4885YTHDC1 2966/4885HSD17B10 2492/4885 |
| US-10233195-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | CYP2C19 4508/4885YTHDC1 4135/4885HSD17B10 2171/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | CYP2C19 4508/4885YTHDC1 4135/4885HSD17B10 2171/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CYP2C19 2192/4885YTHDC1 2966/4885HSD17B10 2492/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | CYP2C19 4508/4885YTHDC1 4135/4885HSD17B10 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.